Company research / EWTX

Edgewise Therapeutics, Inc. (EWTX)

Build a valuation ↗↓ Download CSV

CIK 0001710072

Key ratios (year ended 2025-12-31)

-32.1%

Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 4/A · 2026-08-17

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.

Period ended	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Operating Income	-$191.41M	-$158.83M	-$114.36M	-$71.66M	-$43.22M	-$17.19M	—
Net Income	-$167.79M	-$133.81M	-$100.16M	-$67.64M	-$42.81M	-$17.12M	—
EPS (Diluted)	$-1.63	$-1.45	$-1.57	$-1.26	$-1.14	$-23.17	—
Total Assets	$552.60M	$486.82M	$340.04M	$367.10M	$285.23M	$131.14M	—
Total Liabilities	$30.35M	$27.60M	$21.20M	$20.39M	$10.85M	$4.34M	—
Shareholders' Equity	$522.26M	$459.22M	$318.83M	$346.72M	$274.38M	-$33.42M	-$16.85M
Cash & Equivalents	$61.15M	$41.67M	$86.10M	$21.99M	$15.57M	$104.92M	—
Operating Cash Flow	-$143.82M	-$109.03M	-$91.95M	-$52.63M	-$33.51M	-$14.63M	—
Capital Expenditures	$256.0K	$1.31M	$5.75M	$5.55M	$668.0K	$203.0K	—
Shares Outstanding	106.25M	94.84M	70.45M	63.26M	49.50M	1.01M	—
Weighted Average Diluted Shares	102.93M	92.41M	63.72M	53.59M	37.53M	739.0K	—
EPS (Basic)	$-1.63	$-1.45	$-1.57	$-1.26	$-1.14	$-23.17	—